United Therapeutics (NASDAQ:UTHR) EVP Sells $4,540,681.00 in Stock

Posted by Brenda Bartman on Jun 4th, 2026

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) EVP Paul Mahon sold 8,300 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $547.07, for a total value of $4,540,681.00. Following the transaction, the executive vice president owned 45,172 shares of the company’s stock, valued at $24,712,246.04. The trade was a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

United Therapeutics Trading Down 0.3%

UTHR stock traded down $1.78 during trading hours on Thursday, hitting $547.69. 411,933 shares of the stock were exchanged, compared to its average volume of 479,197. The company has a 50-day simple moving average of $567.74 and a two-hundred day simple moving average of $518.04. The firm has a market capitalization of $23.25 billion, a P/E ratio of 20.22, a P/E/G ratio of 1.75 and a beta of 0.57. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $6.63 earnings per share. On average, equities research analysts predict that United Therapeutics Corporation will post 26.92 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on UTHR. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Cantor Fitzgerald boosted their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. HC Wainwright upped their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. Royal Bank Of Canada cut their target price on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Finally, UBS Group boosted their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $619.42.

Check Out Our Latest Report on UTHR

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Wellington Management Group LLP lifted its holdings in shares of United Therapeutics by 74.5% in the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after purchasing an additional 1,042,711 shares in the last quarter. Darwin Global Management Ltd. purchased a new position in shares of United Therapeutics in the 3rd quarter valued at $317,617,000. Norges Bank acquired a new stake in shares of United Therapeutics during the fourth quarter worth about $293,418,000. Avoro Capital Advisors LLC boosted its position in United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after purchasing an additional 383,838 shares during the period. Finally, Janus Henderson Group PLC raised its stake in shares of United Therapeutics by 75.1% in the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock valued at $387,801,000 after purchasing an additional 341,383 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

About United Therapeutics

(Get Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.